Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn
This page contains brief information about asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Asparaginase erwinia chrysanthemi (recombinant)-rywn is approved to treat adults and children aged 1 month and older with:
Asparaginase erwinia chrysanthemi (recombinant)-rywn is used in patients who can no longer take asparaginase made from E. coli. It is a recombinant form of asparaginase made from the bacterium Erwinia chrysanthemi.
This drug is also available in a non-recombinant form. For more information, see the Drug Information Summary for Asparaginase Erwinia Chrysanthemi.
More About Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn - Check for trials from NCI's list of cancer clinical trials now accepting patients.